Prostate cancer reactivates developmental epigenomic programs during metastatic progression.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
08 2020
Historique:
received: 30 07 2019
accepted: 16 06 2020
pubmed: 22 7 2020
medline: 27 10 2020
entrez: 22 7 2020
Statut: ppublish

Résumé

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the dependency of PCa cells on the androgen receptor (AR), a prostate master transcription factor. We generated 268 epigenomic datasets spanning two state transitions-from normal prostate epithelium to localized PCa to metastases-in specimens derived from human tissue. We discovered that reprogrammed AR sites in metastatic PCa are not created de novo; rather, they are prepopulated by the transcription factors FOXA1 and HOXB13 in normal prostate epithelium. Reprogrammed regulatory elements commissioned in metastatic disease hijack latent developmental programs, accessing sites that are implicated in prostate organogenesis. Analysis of reactivated regulatory elements enabled the identification and functional validation of previously unknown metastasis-specific enhancers at HOXB13, FOXA1 and NKX3-1. Finally, we observed that prostate lineage-specific regulatory elements were strongly associated with PCa risk heritability and somatic mutation density. Examining prostate biology through an epigenomic lens is fundamental for understanding the mechanisms underlying tumor progression.

Identifiants

pubmed: 32690948
doi: 10.1038/s41588-020-0664-8
pii: 10.1038/s41588-020-0664-8
pmc: PMC10007911
mid: NIHMS1864239
doi:

Substances chimiques

Hepatocyte Nuclear Factor 3-alpha 0
Receptors, Androgen 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

790-799

Subventions

Organisme : NCI NIH HHS
ID : P50 CA097186
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM107427
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092131
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA262577
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA163227
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA218530
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251555
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA193910
Pays : United States

Références

Nat Commun. 2016 Apr 07;7:10979
pubmed: 27052111
Genome Res. 2005 Aug;15(8):1034-50
pubmed: 16024819
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Nat Protoc. 2018 May;13(5):819-839
pubmed: 29599440
Hum Pathol. 2017 Mar;61:26-32
pubmed: 27818287
Cell. 2007 Feb 23;128(4):635-8
pubmed: 17320500
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Cancer Res. 1968 Sep;28(9):1908-14
pubmed: 5676741
Cancer Res. 2008 Apr 1;68(7):2479-88
pubmed: 18381457
Dev Dyn. 2013 Oct;242(10):1160-71
pubmed: 23813564
Nat Med. 2018 Feb;24(2):176-185
pubmed: 29334376
Cell. 2009 Jul 23;138(2):245-56
pubmed: 19632176
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
Science. 2016 Jun 24;352(6293):1576-80
pubmed: 27339988
Nat Genet. 2005 Oct;37(10):1047-54
pubmed: 16142232
Cancer Cell. 2019 Mar 18;35(3):401-413.e6
pubmed: 30773341
Endocr Relat Cancer. 2019 May;26(5):R267-R285
pubmed: 30865928
Cancer Res. 2009 Mar 1;69(5):1739-47
pubmed: 19223557
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Stem Cells. 2015 Nov;33(11):3356-67
pubmed: 26220362
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Science. 2015 Feb 13;347(6223):713-4
pubmed: 25678644
Genome Biol. 2012 Oct 03;13(10):R83
pubmed: 23034175
Cancer Res. 2020 Jun 15;80(12):2427-2436
pubmed: 32094298
Cell. 2018 Apr 5;173(2):386-399.e12
pubmed: 29625054
Nat Commun. 2018 Jul 6;9(1):2626
pubmed: 29980679
Bioinformatics. 2015 Nov 15;31(22):3673-5
pubmed: 26163694
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6810-6815
pubmed: 29844167
Bioinformatics. 2009 Jul 15;25(14):1841-2
pubmed: 19468054
Cancer Res. 1983 Apr;43(4):1809-18
pubmed: 6831420
Nat Genet. 2017 Sep;49(9):1336-1345
pubmed: 28783165
Nature. 2012 Jun 20;486(7403):405-9
pubmed: 22722202
Cancer Res. 2012 Jan 15;72(2):527-36
pubmed: 22108827
Science. 2013 Mar 29;339(6127):1567-70
pubmed: 23539597
Nat Genet. 2015 Nov;47(11):1346-51
pubmed: 26457646
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Nature. 2011 Oct 12;478(7370):476-82
pubmed: 21993624
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Cell. 2019 Nov 27;179(6):1330-1341.e13
pubmed: 31761532
Genes Dev. 1999 Apr 15;13(8):966-77
pubmed: 10215624
Oncogene. 2008 Dec 4;27(57):7180-91
pubmed: 18794802
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Cell. 2013 Aug 15;154(4):888-903
pubmed: 23953118
Nat Genet. 2015 Nov;47(11):1228-35
pubmed: 26414678
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
Mol Endocrinol. 2003 Aug;17(8):1484-507
pubmed: 12750453
Cell. 2019 Mar 21;177(1):101-114
pubmed: 30901533
Oncogene. 2018 Nov;37(47):6136-6151
pubmed: 29995873
BMC Bioinformatics. 2016 Oct 3;17(1):404
pubmed: 27716038
Cancer Cell. 2019 Dec 9;36(6):674-689.e6
pubmed: 31735626
Mol Oncol. 2017 Mar;11(3):251-265
pubmed: 28133913
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
Oncotarget. 2017 May 23;8(21):35376-35389
pubmed: 28430640
Science. 1977 Jun 10;196(4295):1161-6
pubmed: 860134
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Dev Biol. 2009 Apr 15;328(2):188-99
pubmed: 19389372
J Comput Biol. 2004;11(2-3):413-28
pubmed: 15285899
Dev Biol. 2012 Nov 15;371(2):246-55
pubmed: 22960283
Cell. 2017 Aug 24;170(5):875-888.e20
pubmed: 28757253
Am J Pathol. 2013 Dec;183(6):1960-1970
pubmed: 24113458
Toxicol Sci. 2013 May;133(1):42-53
pubmed: 23429912
Bioinformatics. 2011 Jun 1;27(11):1571-2
pubmed: 21493656
Theranostics. 2019 Aug 14;9(21):6063-6079
pubmed: 31534537
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Nat Rev Cancer. 2018 Feb;18(2):117-127
pubmed: 29192213
Development. 2003 May;130(10):2061-9
pubmed: 12668621
Nat Methods. 2017 Oct;14(10):959-962
pubmed: 28846090
Development. 2008 Mar;135(6):995-1003
pubmed: 18296651
Nat Genet. 2018 Jul;50(7):928-936
pubmed: 29892016
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
Nat Med. 2018 Sep;24(9):1469-1480
pubmed: 30038216
EMBO Mol Med. 2015 Sep 27;7(11):1450-64
pubmed: 26412853
Cell. 2018 Jul 12;174(2):422-432.e13
pubmed: 29909987
Nat Rev Cancer. 2017 Aug;17(8):502-508
pubmed: 28643779
Nat Commun. 2018 Nov 21;9(1):4900
pubmed: 30464211
Development. 2017 Apr 15;144(8):1382-1398
pubmed: 28400434
Nat Commun. 2020 Jan 23;11(1):441
pubmed: 31974375
PLoS One. 2012;7(4):e34219
pubmed: 22514625
Cell Stem Cell. 2017 Feb 2;20(2):191-204.e5
pubmed: 27889319
Cell. 2018 Jul 12;174(2):433-447.e19
pubmed: 29909985
Genome Biol. 2018 Nov 7;19(1):190
pubmed: 30404658
Nat Protoc. 2017 Dec;12(12):2478-2492
pubmed: 29120462
Nat Rev Cancer. 2001 Oct;1(1):34-45
pubmed: 11900250
Nature. 2015 Jul 16;523(7560):313-7
pubmed: 26153859
Life Sci Alliance. 2018 Dec 28;2(1):e201800115
pubmed: 30620009
Biostatistics. 2019 Jul 1;20(3):367-383
pubmed: 29481604
Nat Commun. 2020 Feb 11;11(1):832
pubmed: 32047165
Prostate. 2017 May;77(6):654-671
pubmed: 28156002

Auteurs

Mark M Pomerantz (MM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Xintao Qiu (X)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Yanyun Zhu (Y)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

David Y Takeda (DY)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.

Wenting Pan (W)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Sylvan C Baca (SC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Alexander Gusev (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Keegan D Korthauer (KD)

Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Tesa M Severson (TM)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Gavin Ha (G)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Srinivas R Viswanathan (SR)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Ji-Heui Seo (JH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Holly M Nguyen (HM)

Department of Urology, University of Washington, Seattle, WA, USA.

Baohui Zhang (B)

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Greater Los Angeles VA Healthcare System, Los Angeles, CA, USA.

Bogdan Pasaniuc (B)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Claudia Giambartolomei (C)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

Sarah A Alaiwi (SA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Connor A Bell (CA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Edward P O'Connor (EP)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Matthew S Chabot (MS)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

David R Stillman (DR)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Rosina Lis (R)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Alba Font-Tello (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Lewyn Li (L)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Paloma Cejas (P)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Andries M Bergman (AM)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Joyce Sanders (J)

Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Henk G van der Poel (HG)

Department of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Simon A Gayther (SA)

Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Kate Lawrenson (K)

Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Marcos A S Fonseca (MAS)

Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Jessica Reddy (J)

Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Rosario I Corona (RI)

Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Gleb Martovetsky (G)

Active Motif, Inc., Carlsbad, CA, USA.

Brian Egan (B)

Active Motif, Inc., Carlsbad, CA, USA.

Toni Choueiri (T)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Leigh Ellis (L)

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.

Isla P Garraway (IP)

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Greater Los Angeles VA Healthcare System, Los Angeles, CA, USA.

Gwo-Shu Mary Lee (GM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Eva Corey (E)

Department of Urology, University of Washington, Seattle, WA, USA.

Henry W Long (HW)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Wilbert Zwart (W)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. w.zwart@nki.nl.
Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands. w.zwart@nki.nl.

Matthew L Freedman (ML)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. mfreedman@partners.org.
The Eli and Edythe L. Broad Institute, Cambridge, MA, USA. mfreedman@partners.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH